According to Zacks, “PolyPid Ltd. is a pharmaceutical company. It discovers, develops and commercializes antibiotic drugs for the prevention of surgical infections. The company’s product candidate includes D-PLEX100, BONYPID-1000 and BONYPID-500 which are in clinical stage. PolyPid Ltd. is based in Petach Tikva, Israel. “
Separately, JMP Securities reaffirmed a “buy” rating and issued a $15.00 price objective on shares of PolyPid in a research note on Thursday, December 16th.
PolyPid (NASDAQ:PYPD) last released its quarterly earnings data on Wednesday, November 10th. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.13. During the same quarter in the prior year, the business earned ($0.35) earnings per share. As a group, equities analysts anticipate that PolyPid will post -2.12 EPS for the current year.
Several hedge funds have recently made changes to their positions in the company. UBS Group AG raised its holdings in shares of PolyPid by 32.7% in the third quarter. UBS Group AG now owns 204,555 shares of the company’s stock valued at $1,592,000 after purchasing an additional 50,395 shares during the last quarter. Millennium Management LLC increased its holdings in PolyPid by 153.5% during the second quarter. Millennium Management LLC now owns 56,530 shares of the company’s stock worth $512,000 after buying an additional 34,227 shares during the last quarter. Meitav Dash Investments Ltd. increased its holdings in PolyPid by 117.2% during the third quarter. Meitav Dash Investments Ltd. now owns 31,500 shares of the company’s stock worth $246,000 after buying an additional 17,000 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its holdings in PolyPid by 22.9% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 24,361 shares of the company’s stock worth $190,000 after buying an additional 4,545 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in PolyPid during the second quarter worth about $174,000. Institutional investors own 8.97% of the company’s stock.
PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PolyPid Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PolyPid and related companies with MarketBeat.com's FREE daily email newsletter.